Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 16,741,573 shares of common stock of Applied Genetic Technologies Corporation and warrants to purchase 8,370,786 shares of common stock of Applied Genetic Technologies Corporation. The common stock is listed on the Nasdaq Global Market under the symbol “AGTC."
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
The Davis Polk corporate team included partners Yasin Keshvargar and Derek Walters and associates David Li and Brooke Zheng. The intellectual property and technology transactions team included counsel Bonnie Chen and associate Daniel P. Kearney. Counsel Kiara L. Rankin provided tax advice. All members of the Davis Polk team are based in the New York office.